Stockreport

FDA approves Alhemo® injection as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophili...

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF bleeds in adults and pediatric patients 12 years of age and older living with hemophilia A or B with inhibitors Results from the pivotal trial showed an 86% reduction [Read more]